A detailed history of United Bank transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, United Bank holds 31,200 shares of TRVI stock, worth $126,360. This represents 0.01% of its overall portfolio holdings.

Number of Shares
31,200
Previous 31,200 -0.0%
Holding current value
$126,360
Previous $92,000 13.04%
% of portfolio
0.01%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.44 - $3.36 $6,710 - $9,240
2,750 Added 9.67%
31,200 $92,000
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.39 $3,150 - $5,932
1,750 Added 6.55%
28,450 $80,000
Q1 2022

May 16, 2022

BUY
$0.46 - $2.48 $12,282 - $66,216
26,700 New
26,700 $59,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $236M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track United Bank Portfolio

Follow United Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Bank, based on Form 13F filings with the SEC.

News

Stay updated on United Bank with notifications on news.